Actelion Ltd., GlaxoSmithKline Stop Development of Insomnia Medicine on Safety Concern
Bloomberg -- Actelion Ltd. and partner GlaxoSmithKline Plc stopped late-stage development of the experimental almorexant insomnia pill because of concern that patients wouldn’t be able to tolerate the medicine.